Prosecution Insights
Last updated: November 06, 2026
Application No. 18/767,297

IMPEDANCE REFLECTOR DETECTION SYSTEMS AND METHODS FOR USING THEM

Non-Final OA §101§102§103§112§DOUBLEPATENT
Filed
Jul 09, 2024
Priority
Oct 04, 2017 — provisional 62/568,208 +2 more
Examiner
DORNA, CARRIE R
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Cianna Medical Inc.
OA Round
1 (Non-Final)
72%
Grant Probability
Favorable
1-2
OA Rounds
1y 0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
668 granted / 924 resolved
+2.3% vs TC avg
Strong +28% interview lift
Without
With
+27.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
31 currently pending
Career history
962
Total Applications
across all art units

Statute-Specific Performance

§101
6.7%
-33.3% vs TC avg
§103
35.8%
-4.2% vs TC avg
§102
20.3%
-19.7% vs TC avg
§112
29.1%
-10.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 924 resolved cases

Office Action

§101 §102 §103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Specification The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Claim Objections Claim 26 is objected to because of the following informalities: “voltage; and activating a light source” should read --voltage; and d) activating a light source--. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites the limitation “the body” in line 9. There is insufficient antecedent basis for this limitation in the claim. Claim 9 recites the limitation “the body” in line 9. There is insufficient antecedent basis for this limitation in the claim. Claim 17 recites the limitations “a light source”, “light pulses”, and “a processor”. It is unclear whether the light source, light pulses, and processor are intended to be the same or different from those of parent claim 9. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 3, 5-9, 11, 13-16, 19, 21, and 23-25 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by U.S. Patent Application Publication No. 2014/0309522 (Fullerton et al.). Regarding claim 1, Fullerton teaches an apparatus for detecting a marker (1040) implanted within tissue that includes an energy converter (1052) coupled to a circuit for changing a configuration of an antenna (1044) of the marker (1040) ([0249]; [0256]; [0261]; [0264]; [0266]; Figures 62-65), the apparatus comprising: 5a set of transmit electrodes coupled to a signal generator for transmitting a drive current into tissue around the marker (1040) (“one or more antennas” including transmit antenna, [0250]; probe 1020 includes signal generator, [0253]); a set of receive electrodes configured to detect voltage signals within the tissue corresponding to impedance of the tissue in response to the drive current (“one or more antennas” including receive antenna, [0250]; probe 1020 includes signal generator, [0253]); a light source for delivering light pulses into the body to cause the energy converter (1052) to 10activate and deactivate the circuit to change the configuration of the antenna (1044) of the marker (1040) ([0261]; [0264]-[0267]); and a processor coupled to the receive electrodes for processing the voltage signals to identify changes in the impedance that are synchronized with the light pulses to determine whether the marker (1040) is operating properly ([0253]; indication of identity/location of tag construed as proper operation, [0270]-[0271]). Regarding claim 3, Fullerton teaches an output device coupled to the processor that provides an indication when the processor determined that the marker (1040) is operating properly (“display…for displaying information to a user of the probe 1020”, [0254]). Regarding claim 5, Fullerton teaches an actuator for activating the light source to deliver the light pulses, the processor configured to process the detected voltage signals 10before activating the light source to determine a threshold voltage and to process the detected voltage signals after the light source is activated to identify changes relative to the threshold voltage ([0251]; [0253]; [0270]-[0271]). Regarding claim 6, Fullerton teaches the signal generator is configured to generate an alternating current between about three and three hundred kilohertz (3-300 kHz) for causing the transmit electrodes to transmit the drive current ([0250]; [0253]). Regarding claims 7 and 8, Fullerton teaches the transmit electrodes and the receive electrodes are provided on a patient contact surface (1032), and wherein the light source is configured to 20deliver the light pulses from the patient contact surface (1032); wherein the patient contact surface (1032) is flat (see Figure 62; [0250]-[0251]). Regarding claim 9, Fullerton teaches a system for localization of a target tissue region within tissue (abstract; [0249]), comprising: a marker (1040) sized for implantation within tissue comprising an energy converter (1052) coupled to a circuit for changing a configuration of an antenna (1044) of the marker (1040) ([0249]; [0256]; [0261]; [0264]; [0266]; Figures 62-65); and an apparatus (Figure 62, probe, 1020) comprising 5a set of transmit electrodes coupled to a signal generator for transmitting a drive current into tissue around the marker (1040) (“one or more antennas” including transmit antenna, [0250]; probe 1020 includes signal generator, [0253]), a set of receive electrodes configured to detect voltage signals within the tissue corresponding to impedance of the tissue in response to the drive current (“one or more antennas” including receive antenna, [0250]; probe 1020 includes signal generator, [0253]), a light source for delivering light pulses into the body to cause the energy converter (1052) to 10activate and deactivate the circuit to change the configuration of the antenna of the marker (1040) ([0261]; [0265]-[0267]), and a processor coupled to the receive electrodes for processing the voltage signals to identify changes in the impedance that are synchronized with the light pulses to determine whether the marker (1040) is operating properly ([0253]; indication of identity/location of tag construed as proper operation, [0270]-[0271]). Regarding claim 11, Fullerton teaches an output device coupled to the processor that provides an indication when the processor determined that the marker (1040) is operating properly (“display…for displaying information to a user of the probe 1020”, [0254]). Regarding claim 13, Fullerton teaches an actuator for activating the light source to deliver the light pulses, the processor configured to process the detected voltage signals 10before activating the light source to determine a threshold voltage and to process the detected voltage signals after the light source is activated to identify changes relative to the threshold voltage ([0251]; [0253]; [0270]-[0271]). Regarding claim 14, Fullerton teaches the signal generator is configured to generate an alternating current between about three and three hundred kilohertz (3-300 kHz) for causing the transmit electrodes to transmit the drive current ([0250]; [0253]). Regarding claims 15 and 16, Fullerton teaches the transmit electrodes and the receive electrodes are provided on a patient contact surface (1032), and wherein the light source is configured to 20deliver the light pulses from the patient contact surface (1032); wherein the patient contact surface (1032) is flat (see Figure 62; [0250]-[0251]). Regarding claim 19, Fullerton teaches a method for localization of a target tissue region within tissue (abstract; [0267]-[0268]), comprising: implanting a marker (Figures 62-64, tag, 1040) within tissue, the marker (1040) comprising an energy converter (Figure 65, power converter, 1052), and a circuit coupled to the energy converter (1052) and an antenna (Figures 62-65, wire, 1044) ([0249]; [0256]; [0261]; [0264]-[0266]); placing an apparatus (Figure 62, probe, 1020) adjacent tissue oriented towards the marker (1040) ([0267]); and activating the apparatus (1020) to a) transmit a drive current via drive electrodes into the tissue (“one or more antennas” including transmit antenna, [0250]; probe 1020 includes signal generator, [0253]; [0267]), b) receive voltage signals from the tissue via receive electrodes corresponding to impedance of the tissue (“one or more antennas” including receive antenna, [0250]; probe 1020 includes signal generator, [0253]; [0267]), c) deliver light pulses into the tissue such that the energy converter (1052) transforms the light pulses to activate and deactivate the circuit to change a configuration of the antenna (1044) [0261]; [0264]-[0267]), and d) 20determine whether changes in the received voltage signals are synchronized with the light pulses to determine whether the marker (1040) is operating properly ([0253]; indication of identity/location of tag construed as proper operation, [0267]; [0270]-[0271]). Regarding claim 21, Fullerton teaches the apparatus provides an output indicating whether the marker (1040) is operating properly (“display…for displaying information to a user of the probe 1020”, [0254]). Regarding claim 23, Fullerton teaches the apparatus (1020) initially activates the light source to deliver the light pulses before activating the light source to determine a threshold voltage and process the detected voltage signals after the light source is activated to identify changes relative to the threshold voltage ([0261]; [0266]-[0267]; [0270]-[0271]). Regarding claim 24, Fullerton teaches the apparatus (1020) comprises a signal generator that generates an alternating current between about three and three hundred kilohertz (3-300 kHz) for causing the transmit electrodes to transmit the drive current ([0250]; [0253]; [0267]). Regarding claim 25, Fullerton teaches the transmit electrodes and the receive electrodes are provided on a patient contact surface (1032) of the apparatus (1020) and the light source is configured to 20deliver the light pulses from the patient contact surface (1032), and wherein placing the apparatus (1020) comprises placing the patient contact surface against the patient’s skin before activating the apparatus (1020) (see Figure 62; [0250]-[0251]; [0267]). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 4, 12, and 22 are rejected under 35 U.S.C. 103 as being unpatentable over U.S. Patent Application Publication No. 2014/0309522 (Fullerton et al.). Regarding claims 4, 12, and 22, Fullerton teaches all the limitations of claim 3, 11, or 22. Fullerton does not expressly teach the output device includes at least one of a light and a speaker providing an output. However, Fullerton teaches an alternative embodiment of an output device (38) coupled to a processor (36) that provides an indication when the processor determines a marker (26) is operating properly ([0111]-[0113]; [0119]-[0121]; [0126]-[0128]; Figure 10); wherein the output device (38) comprises at least one of a light that is activated and a speaker emitting a predetermined sound ([0126]-[0128]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the output device of Figure 62 Fullerton to include a light and a speaker communicating visual and auditory information, respectively, to a practitioner as taught by Figure 10 of Fullerton, because Fullerton teaches providing such a light and speaker enables the provision of “spatial information, operation parameters”, sound or visual output indicating “when the probe 30 reaches a predetermined threshold distance from the marker, e.g., a desired margin, or may be activated when successively closer distances are achieved” ([0127]). Double Patenting A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957). A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101. Claims 26-29 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 23-26 of prior U.S. Patent No. 11,350,846. This is a statutory double patenting rejection. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-25 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-of U.S. Patent No. 11,350,846. Although the claims at issue are not identical, they are not patentably distinct from each other because claim 1 of the instant application is merely broader in scope than all that is recited in claim 1 of the ‘846 patent. That is, claim 1 is anticipated by claim 1 of the ‘846 patent. Similarly, claim 9 is anticipated by claim 7 of the ‘846 patent. Claim 19 is anticipated by claim 17 of the ‘846 patent. Once applicant has received a patent for a species or a more specific embodiment, applicant is not entitled to a patent for the generic or broader invention (see In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993)). Claims 2-8, 10-18, and 20-25 of the instant application are anticipated by claims 1-22 of the ‘846 patent, by the same reasoning. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. US 2014/0309522 (Fullerton et al.): apparatus, system, method for localizing markers in a patient’s body Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carrie R Dorna whose telephone number is (571)270-7483. The examiner can normally be reached 8am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Alexander Valvis can be reached at 571-272-4233. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CARRIE R DORNA/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Jul 09, 2024
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778840
MALE SEXUAL STIMULATION TOY
3y 9m to grant Granted Nov 03, 2026
Patent 12766330
STIMULATION ARRANGEMENT AND METHOD OF ACTIVATING A PATIENT
4y 0m to grant Granted Oct 20, 2026
Patent 12727817
INTELLIGENT AROMATHERAPY SYSTEM
4y 9m to grant Granted Sep 08, 2026
Patent 12714593
SLEEVE FOR PLACING ON A HUMAN PENIS
1y 11m to grant Granted Aug 25, 2026
Patent 12708405
RELEASABLE FLUID CONTROLLER AND INSEMINATION DEVICE
3y 8m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
72%
Grant Probability
99%
With Interview (+27.9%)
3y 4m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 924 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month